ABBOTT LABORATORIES acquires Kos Pharmaceuticals, Inc.

ABBOTT LABORATORIES acquired Kos Pharmaceuticals, Inc. for $78.00 per share in cash (approximately $3.7 billion), a transaction completed in December 2006, structured as all cash (tender offer and merger).

Kos Pharmaceuticals, Inc. operates in Pharmaceuticals — cardiometabolic / lipid management, is based in Cranbury, New Jersey, USA. Kos Pharmaceuticals is a specialty pharmaceutical company focused on cardiometabolic and respiratory products, including the Niaspan and Advicor lipid-management franchises.

Adds a complementary portfolio of cardiometabolic and lipid-management products to Abbott's pharmaceutical franchise.

Complementary lipid-management and cardiometabolic franchise; shareholders owning ~53% of shares committed to tender, assuring closing. Integrated into Abbott's pharmaceutical business

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.